{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:17:41Z","timestamp":1789615061193,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00259-025-07131-3","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T04:37:31Z","timestamp":1739594251000},"page":"2792-2803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET\/CT imaging"],"prefix":"10.1007","volume":"52","author":[{"given":"Huanhuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shina","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-5180","authenticated-orcid":false,"given":"Jinming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"7131_CR1","doi-asserted-by":"publisher","unstructured":"Wang L, Lu B, He M, et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10. https:\/\/doi.org\/10.3389\/fpubh.2022.811044.","DOI":"10.3389\/fpubh.2022.811044"},{"issue":"3","key":"7131_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer. J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"J Clin"},{"key":"7131_CR3","doi-asserted-by":"publisher","unstructured":"Fendler WP, Calais J, Eiber M, et al. Assessment of 68ga-psma-11 pet accuracy in localizing recurrent prostate cancer. JAMA Oncol. 2019;5(6). https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","DOI":"10.1001\/jamaoncol.2019.0096"},{"issue":"10231","key":"7131_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/s0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen pet-ct in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (propsma): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(20)30314-7.","journal-title":"Lancet"},{"issue":"5","key":"7131_CR5","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, et al. Psma pet\/ct: joint eanm procedure guideline\/snmmi procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7131_CR6","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2024.10.004","author":"E Mena","year":"2024","unstructured":"Mena E, Lindenberg L, Choyke PL. Update on psma-based prostate cancer imaging. Semin Nucl Med. 2024. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.10.004.","journal-title":"Semin Nucl Med"},{"key":"7131_CR7","doi-asserted-by":"publisher","unstructured":"Meher N, Vanbrocklin HF, Wilson DM, et al. Psma-targeted nanotheranostics for imaging and radiotherapy of prostate cancer. Pharmaceuticals. 2023;16(2). https:\/\/doi.org\/10.3390\/ph16020315.","DOI":"10.3390\/ph16020315"},{"key":"7131_CR8","doi-asserted-by":"publisher","unstructured":"Milot M-C, Benesty OB, Dumulon-Perreault V, et al. 64cu-dotha2-psma, a novel psma pet radiotracer for prostate cancer with a long imaging time window. Pharmaceuticals. 2022;15(8). https:\/\/doi.org\/10.3390\/ph15080996.","DOI":"10.3390\/ph15080996"},{"key":"7131_CR9","doi-asserted-by":"publisher","unstructured":"Krasnovskaya OO, Abramchuck D, Erofeev A, et al. Recent advances in 64cu\/67cu-based radiopharmaceuticals. Int J Mol Sci. 2023;24(11). https:\/\/doi.org\/10.3390\/ijms24119154.","DOI":"10.3390\/ijms24119154"},{"key":"7131_CR10","doi-asserted-by":"publisher","first-page":"108875","DOI":"10.1016\/j.nucmedbio.2024.108875","volume":"128\u2013129","author":"BJB Nelson","year":"2024","unstructured":"Nelson BJB, Leier S, Wilson J, et al. 64cu production via the 68zn(p,n\u03b1)64cu nuclear reaction: an untapped, cost-effective and high energy production route. Nucl Med Biol. 2024;128\u2013129:108875. https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108875.","journal-title":"Nucl Med Biol"},{"key":"7131_CR11","doi-asserted-by":"publisher","unstructured":"Lee I, Kim MH, Lee K, et al. Comparison of the effects of dota and nota chelators on 64cu-cudotadipep and 64cu-cunotadipep for prostate cancer. Diagnostics. 2023;13(16). https:\/\/doi.org\/10.3390\/diagnostics13162649.","DOI":"10.3390\/diagnostics13162649"},{"issue":"7","key":"7131_CR12","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.2967\/jnumed.108.061739","volume":"50","author":"Z Liu","year":"2009","unstructured":"Liu Z, Li Z-B, Cao Q, et al. Small-animal pet of tumors with 64cu-labeled rgd-bombesin heterodimer. J Nucl Med. 2009;50(7):1168\u201377. https:\/\/doi.org\/10.2967\/jnumed.108.061739.","journal-title":"J Nucl Med"},{"issue":"1","key":"7131_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41181-020-00119-4","volume":"6","author":"H Yang","year":"2021","unstructured":"Yang H, Gao F, Mcneil B, et al. Synthesis of dota-pyridine chelates for 64cu coordination and radiolabeling of \u03b1msh peptide. EJNMMI Radiopharmacy Chem. 2021;6(1):3. https:\/\/doi.org\/10.1186\/s41181-020-00119-4.","journal-title":"EJNMMI Radiopharmacy Chem"},{"issue":"7","key":"7131_CR14","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1016\/j.cclet.2022.02.070","volume":"33","author":"X Chen","year":"2022","unstructured":"Chen X, Niu W, Du Z, et al. 64cu radiolabeled nanomaterials for positron emission tomography (pet) imaging. Chin Chem Lett. 2022;33(7):3349\u201360. https:\/\/doi.org\/10.1016\/j.cclet.2022.02.070.","journal-title":"Chin Chem Lett"},{"issue":"1","key":"7131_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.119.229054","volume":"61","author":"J Carlos Dos Santos","year":"2020","unstructured":"Carlos Dos Santos J, Beijer B, Bauder-W\u00fcst U, et al. Development of novel psma ligands for imaging and therapy with copper isotopes. J Nucl Med. 2020;61(1):70\u20139. https:\/\/doi.org\/10.2967\/jnumed.119.229054.","journal-title":"J Nucl Med"},{"issue":"3","key":"7131_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00259-011-1992-9","volume":"39","author":"J Malmberg","year":"2011","unstructured":"Malmberg J, Perols A, Varasteh Z, et al. Comparative evaluation of synthetic anti-her2 affibody molecules site-specifically labelled with 111in using n-terminal dota, nota and nodaga chelators in mice bearing prostate cancer xenografts. Eur J Nucl Med Mol Imaging. 2011;39(3):481\u201392. https:\/\/doi.org\/10.1007\/s00259-011-1992-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7131_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07000-5","author":"J Zhang","year":"2024","unstructured":"Zhang J, Niu S, Liu Y, et al. Real-time diagnosis of sampled lesions in targeted biopsy of prostate cancer using a novel tracer [64cu] cu-dota-psma-3q: a pilot preclinical study. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-07000-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7131_CR18","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1007\/s00259-022-05775-z","volume":"49","author":"Y Wu","year":"2022","unstructured":"Wu Y, Zhang X, Zhou H, et al. Synthesis, preclinical evaluation, and first-in-human study of al18f-psma-q for prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2022;49(8):2774\u201385. https:\/\/doi.org\/10.1007\/s00259-022-05775-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7131_CR19","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1021\/jm401921j","volume":"57","author":"SR Banerjee","year":"2014","unstructured":"Banerjee SR, Pullambhatla M, Foss CA, et al. 64cu-labeled inhibitors of prostate-specific membrane antigen for pet imaging of prostate cancer. J Med Chem. 2014;57(6):2657\u201369. https:\/\/doi.org\/10.1021\/jm401921j.","journal-title":"J Med Chem"},{"key":"7131_CR20","doi-asserted-by":"publisher","unstructured":"Hagemeyer CE, Gourni E, Canovas C, et al. (r)-nodaga-psma: a versatile precursor for radiometal labeling and nuclear imaging of psma-positive tumors. PLoS ONE. 2015;10(12). https:\/\/doi.org\/10.1371\/journal.pone.0145755.","DOI":"10.1371\/journal.pone.0145755"},{"issue":"9","key":"7131_CR21","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","volume":"48","author":"IL Alberts","year":"2021","unstructured":"Alberts IL, Seide SE, Mingels C, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(9):2978\u201389. https:\/\/doi.org\/10.1007\/s00259-021-05210-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"7131_CR22","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1007\/s00259-021-05426-9","volume":"48","author":"T Liu","year":"2021","unstructured":"Liu T, Liu C, Zhang Z, et al. 64cu-psma-bch: a new radiotracer for delayed pet imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(13):4508\u201316. https:\/\/doi.org\/10.1007\/s00259-021-05426-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7131_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/1874471012666190515090755","volume":"12","author":"F Calabria","year":"2019","unstructured":"Calabria F, Pichler R, Leporace M, et al. 68ga\/64cu psma bio-distribution in prostate cancer patients: potential pitfalls for different tracers. Curr Radiopharmaceuticals. 2019;12(3):238\u201346. https:\/\/doi.org\/10.2174\/1874471012666190515090755.","journal-title":"Curr Radiopharmaceuticals"},{"key":"7131_CR24","doi-asserted-by":"publisher","unstructured":"Mou L, Martini P, Pupillo G, et al. 67cu production capabilities: a mini review. Molecules. 2022;27(5). https:\/\/doi.org\/10.3390\/molecules27051501.","DOI":"10.3390\/molecules27051501"},{"key":"7131_CR25","doi-asserted-by":"publisher","unstructured":"Huynh TT, Van Dam EM, Sreekumar S, et al. Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer. Pharmaceuticals. 2022;15(6). https:\/\/doi.org\/10.3390\/ph15060728.","DOI":"10.3390\/ph15060728"},{"issue":"1","key":"7131_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1039\/c3cs60304k","volume":"43","author":"EW Price","year":"2014","unstructured":"Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014;43(1):260\u201390. https:\/\/doi.org\/10.1039\/c3cs60304k.","journal-title":"Chem Soc Rev"},{"issue":"24","key":"7131_CR27","doi-asserted-by":"publisher","first-page":"8674","DOI":"10.1158\/1078-0432.Ccr-04-1084","volume":"10","author":"JE Sprague","year":"2004","unstructured":"Sprague JE, Peng Y, Sun X, et al. Preparation and biological evaluation of copper-64\u2013labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res. 2004;10(24):8674\u201382. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-1084.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"7131_CR28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12325-018-0711-3","volume":"35","author":"S Sevcenco","year":"2018","unstructured":"Sevcenco S, Klingler HC, Eredics K, et al. Application of cu-64 nodaga-psma pet in prostate cancer. Adv Therapy. 2018;35(6):779\u201384. https:\/\/doi.org\/10.1007\/s12325-018-0711-3.","journal-title":"Adv Therapy"},{"key":"7131_CR29","doi-asserted-by":"publisher","unstructured":"Bachmann MP, Zhang Y, Hong H, et al. Positron emission tomography imaging of cd105 expression with a 64cu-labeled monoclonal antibody: Nota is superior to dota. PLoS ONE. 2011;6(12). https:\/\/doi.org\/10.1371\/journal.pone.0028005.","DOI":"10.1371\/journal.pone.0028005"},{"issue":"1","key":"7131_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1089\/cbr.2017.2337","volume":"33","author":"M Guleria","year":"2018","unstructured":"Guleria M, Das T, Amirdhanayagam J, et al. Comparative evaluation of using nota and dota derivatives as bifunctional chelating agents in the preparation of 68ga-labeled porphyrin: impact on pharmacokinetics and tumor uptake in a mouse model. Cancer Biotherapy Radiopharmaceuticals. 2018;33(1):8\u201316. https:\/\/doi.org\/10.1089\/cbr.2017.2337.","journal-title":"Cancer Biotherapy Radiopharmaceuticals"},{"key":"7131_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.09.020","author":"Y-H Dai","year":"2024","unstructured":"Dai Y-H, Chen P-H, Lee D-J, et al. A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising lutetium-177 and actinium-225 in metastatic prostate cancer. Eur Urol. 2024. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.020.","journal-title":"Eur Urol"},{"issue":"9","key":"7131_CR32","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2967\/jnumed.118.222307","volume":"60","author":"NJ Rupp","year":"2019","unstructured":"Rupp NJ, Umbricht CA, Pizzuto DA, et al. First clinicopathologic evidence of a non\u2013psma-related uptake mechanism for 68ga-psma-11 in salivary glands. J Nucl Med. 2019;60(9):1270\u20136. https:\/\/doi.org\/10.2967\/jnumed.118.222307.","journal-title":"J Nucl Med"},{"issue":"5","key":"7131_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2967\/jnumed.118.207993","volume":"59","author":"D Ta\u00efeb","year":"2018","unstructured":"Ta\u00efeb D, Foletti J-M, Bardi\u00e8s M, et al. Psma-targeted radionuclide therapy and salivary gland toxicity: why does it matter? J Nucl Med. 2018;59(5):747\u20138. https:\/\/doi.org\/10.2967\/jnumed.118.207993.","journal-title":"J Nucl Med"},{"key":"7131_CR34","doi-asserted-by":"publisher","unstructured":"Muniz M, Loprinzi CL, Orme JJ, et al. Salivary toxicity from psma-targeted radiopharmaceuticals: what we have learned and where we are going. Cancer Treat Rev. 2024;127. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102748.","DOI":"10.1016\/j.ctrv.2024.102748"},{"key":"7131_CR35","doi-asserted-by":"publisher","unstructured":"Heynickx N, Segers C, Coolkens A, et al. Characterization of non-specific uptake and retention mechanisms of [177lu]lu-psma-617 in the salivary glands. Pharmaceuticals. 2023;16(5). https:\/\/doi.org\/10.3390\/ph16050692.","DOI":"10.3390\/ph16050692"},{"issue":"5","key":"7131_CR36","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/hed.27307","volume":"45","author":"AN Weaver","year":"2023","unstructured":"Weaver AN, Lakritz S, Mandair D, et al. A molecular guide to systemic therapy in salivary gland carcinoma. Head Neck. 2023;45(5):1315\u201326. https:\/\/doi.org\/10.1002\/hed.27307.","journal-title":"Head Neck"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07131-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07131-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07131-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:22:59Z","timestamp":1749705779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07131-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7131"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07131-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Chinese PLA General Hospital (approval of No. S2023-208-02, Registration number of ChiCTR2300072655).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have read this manuscript and would like to have it considered exclusively for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}